Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of “Moderate Buy” from Brokerages

Ocular Therapeutix, Inc. (NASDAQ:OCUL) has earned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $16.71.

A number of research firms have issued reports on OCUL. Scotiabank started coverage on Ocular Therapeutix in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $22.00 price target for the company. Robert W. Baird cut their target price on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Finally, HC Wainwright increased their price target on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, November 15th.

Ocular Therapeutix Stock Performance

Shares of OCUL opened at $9.89 on Wednesday. The firm has a market capitalization of $1.55 billion, a P/E ratio of -7.49 and a beta of 1.26. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix has a one year low of $2.44 and a one year high of $11.77. The business has a fifty day moving average of $9.98 and a 200 day moving average of $8.28.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Jeffrey S. Heier sold 2,948 shares of the business’s stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $9.01, for a total value of $26,561.48. Following the transaction, the insider now directly owns 269,059 shares in the company, valued at $2,424,221.59. The trade was a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 3.50% of the company’s stock.

Institutional Trading of Ocular Therapeutix

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Deltec Asset Management LLC lifted its stake in Ocular Therapeutix by 9.6% in the 2nd quarter. Deltec Asset Management LLC now owns 2,590,265 shares of the biopharmaceutical company’s stock worth $17,717,000 after purchasing an additional 226,181 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Ocular Therapeutix by 1,142.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 662,672 shares of the biopharmaceutical company’s stock valued at $6,031,000 after buying an additional 609,328 shares during the last quarter. Vanguard Group Inc. boosted its stake in Ocular Therapeutix by 41.4% during the first quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company’s stock valued at $65,840,000 after buying an additional 2,117,029 shares during the last quarter. Cetera Advisors LLC grew its holdings in Ocular Therapeutix by 1,455.0% during the 1st quarter. Cetera Advisors LLC now owns 723,490 shares of the biopharmaceutical company’s stock valued at $6,584,000 after buying an additional 676,963 shares in the last quarter. Finally, Banco Santander S.A. increased its stake in Ocular Therapeutix by 81.3% in the 2nd quarter. Banco Santander S.A. now owns 377,368 shares of the biopharmaceutical company’s stock worth $2,581,000 after acquiring an additional 169,172 shares during the last quarter. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.